Search

Search by keyword or author

Epigenetic Remodeling in Alzheimer’s Disease: Mechanistic Insights and Therapeutic Opportunities

Home > 2026, Volume 14 and Issue 1 > Epigenetic Remodeling in Alzheimer’s Disease: Mechanistic Insights and Therapeutic Opportunities
Published: September 18, 2026
Download PDF
Download HTML

Authors

Amanpreet Kaur, Geeta Aggarwal and Vetriselvan Subramaniyam

DOI Number
https://doi.org/10.15415/jptrm.2026.141003
Keywords
Alzheimer’s disease, Biomarkers, Epigenetics, Histone modifications, Therapeutics

Abstract

Background: Alzheimer’s Disease (AD) is the most prevalent neurodegenerative disorder and a leading cause of dementia, involving the gradual loss of cognitive function, memory, and neurons. While the accumulation of amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs), caused by hyperphosphorylation of the protein tau, continue to be recognized as hallmarks of AD pathology, emerging evidence suggests that epigenetic dysregulation plays a crucial role in disease initiation and progression.

Purpose: The current review highlights the role of epigenetic remodeling in AD pathogenesis, emerging biomarkers associated with epigenetics, therapeutic strategies, and translational challenges.

Methods: This narrative review was conducted through a structured literature search of PubMed, Scopus, and Web of Science databases following the PRISMA framework. Relevant studies on epigenetic mechanisms, biomarkers, and therapeutic strategies in AD were screened and critically reviewed.

Results: Epigenetic mechanisms, including DNA methylation, histone modifications, and non-coding RNA-mediated regulation, affect gene expression without changing the underlying DNA sequence and serve as a critical interface between genetic susceptibility, aging, and environment. Aberrant DNA methylation, changes in histone acetylation, methylation, phosphorylation, and ubiquitination, along with the dysregulation of microRNAs and long noncoding RNA, all play a role in amyloidosis, tauopathy, inflammation, oxidative damage, synaptic dysfunction, and neuronal loss. Additionally, several biomarkers related to epigenetics such as ANK1 methylation, miR-29a/b, miR-107, miR-132, miR-146a, and BACE1-AS have been discovered as potential disease biomarkers. Epigenetic therapeutics involving histone deacetylase inhibitors, DNA methyltransferase regulators, sirtuin-targeting agents, and RNA-based therapeutics have demonstrated neuroprotective effects in preclinical models of AD. Nevertheless, there are certain obstacles that limit their utility, such as insufficient blood-brain barrier (BBB) permeability, off-target effects, and poor clinical translation.

Conclusion: Advancing our understanding of the epigenetic landscape of AD may facilitate the development of precision diagnostics and disease-modifying therapies.

References

  • Alonso, A. D. C., Li, B., Grundke-Iqbal, I., & Iqbal, K. (2008). Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies. Current Alzheimer Research, 5(4), 375–384. https://doi.org/10.2174/156720508785132307
  • Anderson, K. W., & Turko, I. V. (2015). Histone post-translational modifications in frontal cortex from human donors with Alzheimer’s disease. Clinical Proteomics, 12(1), 26. https://doi.org/10.1186/s12014-015-9098-1
  • Balmik, A. A., & Chinnathambi, S. (2021). Methylation as a key regulator of Tau aggregation and neuronal health in Alzheimer’s disease. Cell Communication and Signaling, 19(1), 51. https://doi.org/10.1186/s12964-021-00732-z
  • Balusu, S., Horré, K., Thrupp, N., Craessaerts, K., Snellinx, A., Serneels, L., … & De Strooper, B. (2023). MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer’s disease. Science, 381(6663), 1176–1182. https://doi.org/10.1126/science.abp9556
  • Benito, E., Urbanke, H., Ramachandran, B., Barth, J., Halder, R., Awasthi, A., … & Fischer, A. (2015). HDAC inhibitor–dependent transcriptome and memory reinstatement in cognitive decline models. The Journal of Clinical Investigation, 125(9), 3572–3584. https://doi.org/10.1172/JCI79942
  • Bird, A. (2002). DNA methylation patterns and epigenetic memory. Genes & Development, 16(1), 6–21. https://doi.org/10.1101/gad.947102
  • Bosch‐Presegué, L., & Vaquero, A. (2015). Sirtuin‐dependent epigenetic regulation in the maintenance of genome integrity. The FEBS Journal, 282(9), 1745–1767. https://doi.org/10.1111/febs.13053
  • Cacabelos, R., & Teijido, O. (2018). Epigenetic drug discovery for Alzheimer’s disease. Epigenetics of Aging and Longevity, 453–495. https://doi.org/10.1016/B978-0-12-811060-7.00022-X
  • Caccamo, A., Branca, C., Piras, I. S., Ferreira, E., Huentelman, M. J., Liang, W. S., … & Oddo, S. (2017). Necroptosis activation in Alzheimer’s disease. Nature Neuroscience, 20(9), 1236–1246. https://doi.org/10.1038/nn.4608
  • Creighton, S. D., Jardine, K. H., Desimone, A., Zmetana, M., Castellano, S., Milite, C., … & Winters, B. D. (2022). Age-dependent attenuation of spatial memory deficits by the histone acetyltransferase p300/CBP-associated factor (PCAF) in 3xTG Alzheimer’s disease mice. Learning & Memory, 29(3), 71–76. https://doi.org/10.1101/lm.053536.121
  • De Jager, P. L., Srivastava, G., Lunnon, K., Burgess, J., Schalkwyk, L. C., Yu, L., … & Bennett, D. A. (2014). Alzheimer’s disease: Early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nature Neuroscience, 17(9), 1156–1163. https://doi.org/10.1038/nn.3786
  • de la Fuente, V., Federman, N., Zalcman, G., Salles, A., Freudenthal, R., & Romano, A. (2015). NF-κB transcription factor role in consolidation and reconsolidation of persistent memories. Frontiers in Molecular Neuroscience, 8, 50. https://doi.org/10.3389/fnmol.2015.00050
  • De Plano, L. M., Saitta, A., Oddo, S., & Caccamo, A. (2024). Epigenetic changes in Alzheimer’s disease: DNA methylation and histone modification. Cells, 13(8), 719. https://doi.org/10.3390/cells13080719
  • Faghihi, M. A., Modarresi, F., Khalil, A. M., Wood, D. E., Sahagan, B. G., Morgan, T. E., … & Wahlestedt, C. (2008). Expression of a noncoding RNA is elevated in Alzheimer’s disease and drives rapid feed-forward regulation of β-secretase. Nature Medicine, 14(7), 723–730. https://doi.org/10.1038/nm1784
  • Federman, N., de la Fuente, V., Zalcman, G., Corbi, N., Onori, A., Passananti, C., & Romano, A. (2013). Nuclear factor κB-dependent histone acetylation is specifically involved in persistent forms of memory. Journal of Neuroscience, 33(17), 7603–7614. https://doi.org/10.1523/JNEUROSCI.4181-12.2013
  • Fenoglio, C., Scarpini, E., Serpente, M., & Galimberti, D. (2018). Role of genetics and epigenetics in the pathogenesis of Alzheimer’s disease and frontotemporal dementia. Journal of Alzheimer’s Disease, 62(3), 913–932. https://doi.org/10.3233/JAD-170702
  • Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M., & Tsai, L. H. (2007). Recovery of learning and memory is associated with chromatin remodelling. Nature, 447(7141), 178–182. https://doi.org/10.1038/nature05772
  • Fujiwara, K., Fujita, Y., Kasai, A., Onaka, Y., Hashimoto, H., Okada, H., & Yamashita, T. (2016). Deletion of JMJD2B in neurons leads to defective spine maturation, hyperactive behavior and memory deficits in mouse. Translational Psychiatry, 6(3), e766–e766. https://doi.org/10.1038/tp.2016.31
  • Garbuz, D. G., Zatsepina, O. G., & Evgen’ev, M. B. (2021). Beta amyloid, tau protein, and neuroinflammation: An attempt to integrate different hypotheses of Alzheimer’s disease pathogenesis. Molecular Biology, 55(5), 670–682. https://doi.org/10.1134/S002689332104004X
  • Geng, H., Chen, H., Wang, H., & Wang, L. (2021). The histone modifications of neuronal plasticity. Neural Plasticity, 2021(1), 6690523. https://doi.org/10.1155/2021/6690523
  • Goel, P., Chakrabarti, S., Goel, K., Bhutani, K., Chopra, T., & Bali, S. (2022). Neuronal cell death mechanisms in Alzheimer’s disease: An insight. Frontiers in Molecular Neuroscience, 15, 937133. https://doi.org/10.3389/fnmol.2022.937133
  • Gonzales, B. J., Mukherjee, D., Ashwal-Fluss, R., Loewenstein, Y., & Citri, A. (2020). Subregion-specific rules govern the distribution of neuronal immediate-early gene induction. Proceedings of the National Academy of Sciences, 117(38), 23304–23310. https://doi.org/10.1073/pnas.1913658116
  • Govindarajan, N., Agis-Balboa, R. C., Walter, J., Sananbenesi, F., & Fischer, A. (2011). Sodium butyrate improves memory function in an Alzheimer’s disease mouse model when administered at an advanced stage of disease progression. Journal of Alzheimer’s Disease, 26(1), 187–197. https://doi.org/10.3233/JAD-2011-110080
  • Gräff, J., & Tsai, L. H. (2013). The potential of HDAC inhibitors as cognitive enhancers. Annual Review of Pharmacology and Toxicology, 53, 311–330. https://doi.org/10.1146/annurev-pharmtox-011112-140216
  • Gräff, J., Rei, D., Guan, J. S., Wang, W. Y., Seo, J., Hennig, K. M., … & Tsai, L. H. (2012). An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature, 483(7388), 222–226. https://doi.org/10.1038/nature10849
  • Green, K. N., Steffan, J. S., Martinez-Coria, H., Sun, X., Schreiber, S. S., Thompson, L. M., & LaFerla, F. M. (2008). Nicotinamide restores cognition in Alzheimer’s disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. Journal of Neuroscience, 28(45), 11500–11510. https://doi.org/10.1523/JNEUROSCI.3203-08.2008
  • Guo, Y., Chomiak, A. A., Hong, Y., Lowe, C. C., Kopsidas, C. A., Chan, W. C., … & Feng, Y. (2022). Histone H2A ubiquitination resulting from Brap loss of function connects multiple aging hallmarks and accelerates neurodegeneration. iScience, 25(7). https://doi.org/10.1016/j.isci.2022.104519
  • Gupta, S., Kim, S. Y., Artis, S., Molfese, D. L., Schumacher, A., Sweatt, J. D., … & Lubin, F. D. (2010). Histone methylation regulates memory formation. Journal of Neuroscience, 30(10), 3589–3599. https://doi.org/10.1523/JNEUROSCI.3732-09.2010
  • He, X., Hui, Z., Xu, L., Bai, R., Gao, Y., Wang, Z., … & Ye, X. Y. (2022). Medicinal chemistry updates of novel HDACs inhibitors (2020 to present). European Journal of Medicinal Chemistry, 227, 113946. https://doi.org/10.1016/j.ejmech.2021.113946
  • Hébert, S. S., Horré, K., Nicolaï, L., Papadopoulou, A. S., Mandemakers, W., Silahtaroglu, A. N., … & De Strooper, B. (2008). Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/β-secretase expression. Proceedings of the National Academy of Sciences, 105(17), 6415–6420. https://doi.org/10.1073/pnas.0710263105
  • Hesson, L. B., & Pritchard, A. L. (2019). Genetics and epigenetics: A historical overview. In Clinical Epigenetics (pp. 1–46). Springer Singapore. https://doi.org/10.1007/978-981-13-8958-0_1
  • Höllmüller, E., Geigges, S., Niedermeier, M. L., Kammer, K. M., Kienle, S. M., Rösner, D., … & Stengel, F. (2021). Site-specific ubiquitylation acts as a regulator of linker histone H1. Nature Communications, 12(1), 3497. https://doi.org/10.1038/s41467-021-23636-5
  • Hwang, J. Y., Aromolaran, K. A., & Zukin, R. S. (2017). The emerging field of epigenetics in neurodegeneration and neuroprotection. Nature Reviews Neuroscience, 18(6), 347–361. https://doi.org/10.1038/nrn.2017.46
  • Hyun, K., Jeon, J., Park, K., & Kim, J. (2017). Writing, erasing and reading histone lysine methylations. Experimental & Molecular Medicine, 49(4), e324–e324. https://doi.org/10.1038/emm.2017.11
  • Julien, C., Tremblay, C., Émond, V., Lebbadi, M., Salem, N., Jr., Bennett, D. A., & Calon, F. (2009). Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. Journal of Neuropathology & Experimental Neurology, 68(1), 48–58. https://doi.org/10.1097/NEN.0b013e3181922348
  • Kaniskan, H. U., Martini, M. L., & Jin, J. (2018). Inhibitors of protein methyltransferases and demethylases. Chemical Reviews, 118(3), 989–1068. https://doi.org/10.1021/acs.chemrev.6b00801
  • Kilgore, M., Miller, C. A., Fass, D. M., Hennig, K. M., Haggarty, S. J., Sweatt, J. D., & Rumbaugh, G. (2010). Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacology, 35(4), 870–880. https://doi.org/10.1038/npp.2009.197
  • Kim, S., Kim, H., & Um, J. W. (2018). Synapse development organized by neuronal activity-regulated immediate-early genes. Experimental & Molecular Medicine, 50(4), 1–7. https://doi.org/10.1038/s12276-018-0025-1
  • Kosik, K. S., Rapp, P. R., Raz, N., Small, S. A., Sweatt, J. D., & Tsai, L. H. (2012). Mechanisms of age-related cognitive change and targets for intervention: Epigenetics. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences, 67(7), 741–746. https://doi.org/10.1093/gerona/gls110
  • Kumar, R., Jain, V., Kushwah, N., Dheer, A., Mishra, K. P., Prasad, D., & Singh, S. B. (2021). HDAC inhibition prevents hypobaric hypoxia-induced spatial memory impairment through PI3K/GSK3β/CREB pathway. Journal of Cellular Physiology, 236(9), 6754–6771. https://doi.org/10.1002/jcp.30337
  • Levenson, J. M., & Sweatt, J. D. (2005). Epigenetic mechanisms in memory formation. Nature Reviews Neuroscience, 6(2), 108–118. https://doi.org/10.1038/nrn1604
  • Li, K., Wei, Q., Liu, F. F., Hu, F., Xie, A. J., Zhu, L. Q., & Liu, D. (2018). Synaptic dysfunction in Alzheimer’s disease: Aβ, tau, and epigenetic alterations. Molecular Neurobiology, 55(4), 3021–3032. https://doi.org/10.1007/s12035-017-0533-3
  • Li, R., Wei, X., & Jiang, D. S. (2019). Protein methylation functions as the posttranslational modification switch to regulate autophagy. Cellular and Molecular Life Sciences, 76(19), 3711–3722. https://doi.org/10.1007/s00018-019-03161-x
  • Lubin, F. D., Roth, T. L., & Sweatt, J. D. (2008). Epigenetic regulation of BDNF gene transcription in the consolidation of fear memory. Journal of Neuroscience, 28(42), 10576–10586. https://doi.org/10.1523/JNEUROSCI.1786-08.2008
  • Lukiw, W. J., Zhao, Y., & Cui, J. G. (2008). An NF-κB-sensitive microRNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. Journal of Biological Chemistry, 283(46), 31315–31322. https://doi.org/10.1074/jbc.M805371200
  • Lunnon, K., Smith, R., Hannon, E., De Jager, P. L., Srivastava, G., Volta, M., … & Mill, J. (2014). Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer’s disease. Nature Neuroscience, 17(9), 1164–1170. https://doi.org/10.1038/nn.3782
  • Mastroeni, D., Grover, A., Delvaux, E., Whiteside, C., Coleman, P. D., & Rogers, J. (2010). Epigenetic changes in Alzheimer’s disease: Decrements in DNA methylation. Neurobiology of Aging, 31(12), 2025–2037. https://doi.org/10.1016/j.neurobiolaging.2008.12.005
  • Morera, L., Lübbert, M., & Jung, M. (2016). Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. Clinical Epigenetics, 8(1), 57. https://doi.org/10.1186/s13148-016-0223-4
  • Nativio, R., Donahue, G., Berson, A., Lan, Y., Amlie-Wolf, A., Tuzer, F., … & Berger, S. L. (2018). Dysregulation of the epigenetic landscape of normal aging in Alzheimer’s disease. Nature Neuroscience, 21(4), 497–505. https://doi.org/10.1038/s41593-018-0101-9
  • Nikolac Perkovic, M., Videtic Paska, A., Konjevod, M., Kouter, K., Svob Strac, D., Nedic Erjavec, G., & Pivac, N. (2021). Epigenetics of Alzheimer’s disease. Biomolecules, 11(2), 195. https://doi.org/10.3390/biom11020195
  • Pal, S., & Tyler, J. K. (2016). Epigenetics and aging. Science Advances, 2(7), e1600584. https://doi.org/10.1126/sciadv.1600584
  • Peixoto, L., & Abel, T. (2013). The role of histone acetylation in memory formation and cognitive impairments. Neuropsychopharmacology, 38(1), 62–76. https://doi.org/10.1038/npp.2012.86
  • Pereira, M., Cruz, M. T., Fortuna, A., & Bicker, J. (2024). Restoring the epigenome in Alzheimer’s disease: Advancing HDAC inhibitors as therapeutic agents. Drug Discovery Today, 29(7), 104052. https://doi.org/10.1016/j.drudis.2024.104052
  • Qin, Q., Yin, Y., Wang, Y., Lu, Y., Tang, Y., & Jia, J. (2020). Gene mutations associated with early onset familial Alzheimer’s disease in China: An overview and current status. Molecular Genetics & Genomic Medicine, 8(10), e1443. https://doi.org/10.1002/mgg3.1443
  • Qing, H., He, G., Ly, P. T., Fox, C. J., Staufenbiel, M., Cai, F., … & Song, W. (2008). Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioral deficits in Alzheimer’s disease mouse models. The Journal of Experimental Medicine, 205(12), 2781–2789. https://doi.org/10.1084/jem.20081588
  • Ricobaraza, A., Cuadrado-Tejedor, M., Pérez-Mediavilla, A., Frechilla, D., Del Río, J., & García-Osta, A. (2009). Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer’s disease mouse model. Neuropsychopharmacology, 34(7), 1721–1732. https://doi.org/10.1038/npp.2008.229
  • Rossetto, D., Avvakumov, N., & Côté, J. (2012). Histone phosphorylation: A chromatin modification involved in diverse nuclear events. Epigenetics, 7(10), 1098–1108. https://doi.org/10.4161/epi.21975
  • Santana, D. A., Bedrat, A., Puga, R. D., Turecki, G., Mechawar, N., Faria, T. C., … & Chen, E. S. (2022). The role of H3K9 acetylation and gene expression in different brain regions of Alzheimer’s disease patients. Epigenomics, 14(11), 651–670. https://doi.org/10.2217/epi-2022-0096
  • Schueller, E., Paiva, I., Blanc, F., Wang, X. L., Cassel, J. C., Boutillier, A. L., & Bousiges, O. (2020). Dysregulation of histone acetylation pathways in hippocampus and frontal cortex of Alzheimer’s disease patients. European Neuropsychopharmacology, 33, 101–116. https://doi.org/10.1016/j.euroneuro.2020.01.015
  • Shukla, S., & Tekwani, B. L. (2020). Histone deacetylases inhibitors in neurodegenerative diseases, neuroprotection and neuronal differentiation. Frontiers in Pharmacology, 11, 537. https://doi.org/10.3389/fphar.2020.00537
  • Smith, P. Y., Hernandez-Rapp, J., Jolivette, F., Lecours, C., Bisht, K., Goupil, C., … & Hébert, S. S. (2015). miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo. Human Molecular Genetics, 24(23), 6721–6735. https://doi.org/10.1093/hmg/ddv377
  • Tajima, S., Suetake, I., Takeshita, K., Nakagawa, A., Kimura, H., & Song, J. (2022). Domain structure of the Dnmt1, Dnmt3a, and Dnmt3b DNA methyltransferases. DNA Methyltransferases—Role and Function, 45–68. https://doi.org/10.1007/978-3-031-11454-0_3
  • Tsankova, N. M., Berton, O., Renthal, W., Kumar, A., Neve, R. L., & Nestler, E. J. (2006). Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nature Neuroscience, 9(4), 519–525. https://doi.org/10.1038/nn1659
  • Vecsey, C. G., Hawk, J. D., Lattal, K. M., Stein, J. M., Fabian, S. A., Attner, M. A., … & Wood, M. A. (2007). Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB: CBP-dependent transcriptional activation. Journal of Neuroscience, 27(23), 6128–6140. https://doi.org/10.1523/JNEUROSCI.0296-07.2007
  • Villa, C., & Combi, R. (2024). Epigenetics in Alzheimer’s disease: A critical overview. International Journal of Molecular Sciences, 25(11), 5970. https://doi.org/10.3390/ijms25115970
  • Wang, W. X., Rajeev, B. W., Stromberg, A. J., Ren, N., Tang, G., Huang, Q., … & Nelson, P. T. (2008). The expression of microRNA miR-107 decreases early in Alzheimer’s disease and may accelerate disease progression through regulation of β-site amyloid precursor protein-cleaving enzyme 1. Journal of Neuroscience, 28(5), 1213–1223. https://doi.org/10.1523/JNEUROSCI.5065-07.2008
  • Wei, J. W., Huang, K., Yang, C., & Kang, C. S. (2017). Non-coding RNAs as regulators in epigenetics. Oncology Reports, 37(1), 3–9. https://doi.org/10.3892/or.2016.5236
  • Xiao, X., Liu, X., & Jiao, B. (2020). Epigenetics: Recent advances and its role in the treatment of Alzheimer’s disease. Frontiers in Neurology, 11, 538301. https://doi.org/10.3389/fneur.2020.538301

How to Cite

Amanpreet Kaur, Geeta Aggarwal and Vetriselvan Subramaniyam. Epigenetic Remodeling in Alzheimer’s Disease: Mechanistic Insights and Therapeutic Opportunities. J. Pharm. Technol. Res. Manag.. 2026, 14, 74-86
Epigenetic Remodeling in Alzheimer’s Disease: Mechanistic Insights and Therapeutic Opportunities

Current Issue

PeriodicityBiannually
Issue-1June
Issue-2December
ISSN Print2321-2217
ISSN Online2321-2225
RNI No.CHAENG/2013/50088

This work is licensed under a Creative Commons Attribution 4.0 International License.

Articles in Journal of Pharmaceutical Technology, Research and Management (J. Pharm. Tech. Res. Management) by Chitkara University Publications are Open Access articles that are published with licensed under a Creative Commons Attribution- CC-BY 4.0 International License. Based on a work at https://jptrm.chitkara.edu.in/. This license permits one to use, remix, tweak and reproduction in any medium, even commercially provided one give credit for the original creation.

View Legal Code of the above-mentioned license, https://creativecommons.org/licenses/by/4.0/legalcode

View Licence Deed here https://creativecommons.org/licenses/by/4.0/

Creative Commons License

Journal of Pharmaceutical Technology, Research and Management by Chitkara University Publications is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at https://jptrm.chitkara.edu.in//

Visibility, Memberships and Ethics

Chitkara University

Chitkara University

India’s top rated university

Chandigarh-Patiala National Highway, Punjab 140 401

Chandigarh Information Center SCO 160-161, Sector 9-C, Chandigarh 160 009

Publisher

Corporate Office

Chitkara University Publications
Administrative Office, Saraswati Kendra
P.O. Box No. 70,
SCO 160-161, Sector- 9C, Chandigarh-160009, India.

Email: chitkarauniversitypublications@chitkara.edu.in

Editorial Office

Centre for Research Impact and Outcome
4th floor, Darwin Block
Chandigarh-Patiala National Highway, Rajpura
Punjab-140401, India
Email: editor.jptrm@chitkara.edu.in, journals@chitkara.edu.in

For journal please visit the website: https://jptrm.chitkara.edu.in/

The "Journal of Pharmaceutical Technology, Research and Management” is a peer-reviewed, refereed, bi-annual open-access Journal of "Chitkara University Publications".

ISSN (p): 2321-2217 ; ISSN (e): 2321-2225 ; RNI No: CHAENG/2013/50088

Copyright ©2026 Chitkara Educational Trust | All rights reserved
Explore Your Potential

Chandigarh-Patiala National Highway, Punjab 140 401

Chandigarh Information Center SCO 160-161, Sector 9-C, Chandigarh 160 009

×
✔

Thank You!

Your form has been submitted successfully.